Staurosporine

製品コードS1421 別名:CGP 41251

Staurosporine化学構造

分子量(MW):466.53

Staurosporineは1種の有効なPKC阻害剤で、無細胞試験でPKCα、PKCγ とPKCηに作用します。そして、これらのIC50値は2 nM、5 nM と 4 nMそれぞれに分かれます。StaurosporineはPKCδ(20 nM)とPKCε(73 nM)に作用することが弱くて、PKCζ (1086 nM)に対する活性も低いですが、他のキナーゼ(例えば、PKA、PKG、S6K、CaMKII等)に抑制活性を現れます。臨床3期。

サイズ 価格(税別)  
JPY 44820.00

カスタマーフィードバック(3)

  • Intracellular concentration of HSF1-phosphoserine 326, total HSF1, S6 kinase-phosphothreonine-389, total S6 kinase and β-actin, without or with heat shock in HeLa cells pretreated with mTOR inhibitors rapamycin (30 nM) and KU0063794 (2 uM) and kinase inhibitor staurosporine (100 nM) for 2 hr. Relative levels of HSF1-phosphoserine 326 in cells after the various treatments were determined by densitometric analysis of X-ray films, normalized to untreated cells (lane 1), and are indicated below the representation of the immunoblots.

    PLoS One 2012 7(6), e39679. Staurosporine purchased from Selleck.

    J Biomol Screen 2013 18(4), 388-99. Staurosporine purchased from Selleck.

  • J Biomol Screen 2013 18(4), 388-99. Staurosporine purchased from Selleck.

製品安全説明書

PKC阻害剤の選択性比較

生物活性

製品説明 Staurosporineは1種の有効なPKC阻害剤で、無細胞試験でPKCα、PKCγ とPKCηに作用します。そして、これらのIC50値は2 nM、5 nM と 4 nMそれぞれに分かれます。StaurosporineはPKCδ(20 nM)とPKCε(73 nM)に作用することが弱くて、PKCζ (1086 nM)に対する活性も低いですが、他のキナーゼ(例えば、PKA、PKG、S6K、CaMKII等)に抑制活性を現れます。臨床3期。
ターゲット
PKCα [1]
(Cell-free assay)
c-Fgr [2]
(Cell-free assay)
phosphorylase kinase [2]
(Cell-free assay)
PKCη [1]
(Cell-free assay)
PKCγ [1]
(Cell-free assay)
2 nM 2 nM 3 nM 4 nM 5 nM
体外試験

Staurosporine, a microbial alkaloid, significantly inhibits protein kinase C from rat brain with IC50 of 2.7 nM. Staurosporine displays strong inhibitory effect against HeLa S3 cells with IC50 of 4 nM. [1] Staurosporine also inhibits a variety of other protein kinases, including PKA, PKG, phosphorylase kinase, S6 kinase, Myosin light chain kinase (MLCK), CAM PKII, cdc2, v-Src, Lyn, c-Fgr, and Syk with IC50 of 15 nM, 18 nM, 3 nM, 5 nM, 21 nM, 20 nM, 9 nM, 6 nM, 20 nM, 2 nM, and 16 nM, respectively. [2] Staurosporine (1 μM) induces >90% apoptosis in PC12 cells. Consistently, Staurosporine treatment induces a rapid and prolonged elevation of intracellular free calcium levels [Ca2+]i, accumulation of mitochondrial reactive oxygen species (ROS), and subsequent mitochondrial dysfunction. [3] The apoptosis of MCF7 cells induced by Staurosporine can be enhanced by the expression of functional caspase-3 via caspase-8 activation and Bid cleavage. [4] Staurosporine treatment at 1 μM only partially inhibits IL-3-stimulated Bcl2 phosphorylation but completely blocks PKC-mediated Bcl2 phosphorylation. [5] Staurosporine induces apoptosis of human foreskin fibroblasts AG-1518, depending on the lysosomal cathepsins D mediated cytochrome c release and caspase activation. [6] In addition to activating the classical mitochondrial apoptosis pathway, Staurosporine triggers a novel intrinsic apoptosis pathway, relying on the activation of caspase-9 in the absence of Apaf-1. [7]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human HeLa cells M3j1c2N6fG:2b4jpZ:Kh[XO|YYm= MXS0PEBp MlH5R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVN[SClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUTlMVA3KM7:TT6= M2fCUlIyOzh6MUmx
human colon cancer cell line (LoVo cells) NHXySWtRem:uaX\ldoF1cW:wIHHzd4F6 M1\ITmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iY3;sc44h[2GwY3XyJINmdGxibHnu[UApVG:YbzDj[YxteylidYPpcochVVSWIHHzd4F6NCCLQ{WwQVAvODBzIN88UU4> MmDJNVE2QTF3MEW=
human LoVo cells MonNVJJwdGmoZYLheIlwdiCjc4PhfS=> M{jDPFQ5KHSxIEeyJIg> M1fkNWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTH;Wc{Bk\WyuczDh[pRmeiB2ODD0c{A4OiCqcoOgZpkhVVSWIHHzd4F6 NYDZfJZqOjJzOEK5Nlk>
P19 cells NIHES3JHfW6ldHnvckBie3OjeR?= NHjicJpKdmirYnn0bY9vKG:oIGDsZZRmdGW2LXTldol3\WRiZ4Lve5RpKG[jY4TvdkBz\WOncITvdkBqdiCSMUmgZ4VtdHNuIFnDOVA:OC5yMEKg{txONg>? MnK5NVU4PzF2MUm=
human BJ cells MWPDfZRwfG:6aXRCpIF{e2G7 NUjpPINTPzJiaB?= NICxO3NEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBDUiClZXzsd{Bi\nSncjC3NkBpenNiYomgR4Ft[2WrbjDBUUBie3OjeTygTWM2OD1yLkCwNkDPxE1w M{HPU|IzQTJzMEix
human HT-29 cells NWTmWml6TnWwY4Tpc44h[XO|YYm= MUGyJIg> MkW4SYZn\WO2IH;uJI1qfG:laH;u[JJq[WxibXXtZpJidmVicH;0[Y51cWGuIHnuJIh2dWGwIFjUMVI6KGOnbHzzJIFnfGW{IEKgbJJ{KHW|aX7nJGpENTFic4ThbY5qdmdiYomg[ox2d3Knc3PlcoNmKGG|c3H5 NF\TbIszOTR{OEO3OS=>
human A549 cells NEftOJFEgXSxdH;4bYPDqGG|c3H5 M33tRlczKGh? NXrqe5VCS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjZoTldkA4OiCqcoOgZpkhe3WuZn;ybI9l[W2rbnWgRkBu\XSqb3S= M2HXVVE5PDh2N{e1
human HT-29 cells NVThfmF{TnWwY4Tpc44h[XO|YYm= MWrJcohq[mm2aX;uJI9nKG2rdH;jbI9v\HKrYXygcYVu[nKjbnWgdI91\W62aXHsJIlvKGi3bXHuJGhVNTJ7IHPlcIx{KHW|aX7nJGpEOSCmeXWgd5RicW6rbnegZpkh\my3b4Lld4NmdmOnIIDsZZRmKHKnYXTldkBie3OjeTygTWM2OD1{LkWgcm0> MU[yNVUyOzJ7Mx?=
human HT-29 cells MlzaSpVv[3Srb36gZZN{[Xl? NXrz[VFnOiCq NEWxdXpKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m|IHnuJIh2dWGwIFjUMVI6KGOnbHzzJIF{e2W|c3XkJJJm\HWldHnvckBw\iCvaYTvZ4hwdmS{aXHsJI1mdWK{YX7lJJBwfGWwdHnhcEBi\nSncjCyJIhzeyCkeTD1d4lv\yCMQ{Ggd5RicW6rbnegZpkh\my3b4Lld4NmdmOnIHPlcIwu[mG|ZXSgZZN{[XluIFXDOVA:Oi54IH7NMi=> M3PYVFIyQTd|MUCx
Sf9 cells MYrGeY5kfGmxbjDhd5NigQ>? M2[0[mlvcGmkaYTpc44hd2ZiaIXtZY4hW3mtIHX4dJJme3OnZDDpckBU\jliY3XscJMtKEmFNUC9N{BvVS5? Ml;BNVg5OjN5OES=
human HUVEC Mn\tVJJwdGmoZYLheIlwdiCjc4PhfS=> MkPyOFghfG9iN{KgbC=> NF32bYlCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjVWmVEKGGodHXyJFQ5KHSxIEeyJIhzeyCkeTDNWHQh[XO|YYm= NIDFTZYzOjF6MkmyPS=>
P19 cells Ml75SpVv[3Srb36gZZN{[Xl? NYn2bmtlUW6qaXLpeIlwdiCxZjDQdo91\WmwIFvpcoF{\SCDIHnuJHAyQSClZXzsd{whUUN3ME20JI5ONg>? Mlq5NVU4PzF2MUm=
Sf9 cells MWLGeY5kfGmxbjDhd5NigQ>? M1LL[mlvcGmkaYTpc44hd2ZiaIXtZY4hTnmwIHX4dJJme3OnZDDpckBU\jliY3XscJMh[W[2ZYKgNUBucW5iYomgSWxKW0FiaX6gdJJme2WwY3Wgc4YhOSC3bX;sM2whSVSS MX6xO|MyPTh3Mx?=
Sf21 cells MnTOSpVv[3Srb36gZZN{[Xl? NEPlbZRKdmirYnn0bY9vKG:oIFrBT|Mh\XiycnXzd4VlKGmwIGPmNlEh[2WubIOsJGlEPTB;NjDuUU4> M{XqeFE4ODh6MEW5
human colon carcinoma cell line HCT116 NUPoN3J5TnWwY4Tpc44h[XO|YYm= MVfDc45k\W62cnH0bY9vKHKncYXpdoVlKG[xcjDndo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDjc4xwdiClYYLjbY5wdWFiY3XscEBtcW6nIFjDWFEyPixiSVO1NF03KG6PLh?= M2nsOVE2PTN5M{S1
human ST486 cells MW\Qdo9tcW[ncnH0bY9vKGG|c3H5 NIribW01QCC2bzC3NkBp MXXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFOWNEi2JINmdGy|IHHmeIVzKDR6IITvJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9O{BvVS5? MWKyNlE5Ojl{OR?=
human MDA-MB-231 cells Mo\ZR5l1d3SxeHnjxsBie3OjeR?= M1TGb|czKGh? MkfTR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDh[pRmeiB5MjDodpMh[nlic4Xs[o9zcG:mYX3pcoUhSiCvZYToc4QtKEeLNUC9O{4yKG6PLh?= M{TkflE5PDh2N{e1
P19 cells NXKy[mpTTnWwY4Tpc44h[XO|YYm= MYTJcohq[mm2aX;uJI9nKEO7Y3zpck1l\XCnbnTlcpQhc2mwYYPlJFEhcW5iUEG5JINmdGy|LDDJR|UxRThibl2u MYqxOVc4OTRzOR?=
human DLD1 cells MkLyVJJwdGmoZYLheIlwdiCjc4PhfS=> NUXzR5FxPDhvN{KgbC=> MXTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKESOREGgZ4VtdHNiYX\0[ZIhPDhidH:gO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME25JI5ONg>? MYiyNlE5Ojl{OR?=
insect cells NG\BVJhHfW6ldHnvckBie3OjeR?= NGPZbnJKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IGDpcVEh\XiycnXzd4VlKGmwIHnud4VkfCClZXzsd{BjgSCKVGLGMEBKSzVyPUGwJI5ONg>? MVmxPVE4QTB5Nh?=
V79 MZ cells NXHFdWJuTnWwY4Tpc44h[XO|YYm= NI[0N3hKdmirYnn0bY9vKG:oIHj1cYFvKGGuZH;zeIVzd26nIIP5cpRp[XOnIHX4dJJme3OnZDDpckBXPzliTWqgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCjbHTvd5Rmem:wZTDzfY51cGW|aYOsJGlEPTB;MUGgcm0v MkmxNlQ1OjJ3MUm=
P19 cells M3jrSWZ2dmO2aX;uJIF{e2G7 NF;KR5ZKdmirYnn0bY9vKG:oIG\hd4N2dGG{IHXu[I91cGWuaXHsJIdzd3e2aDDmZYN1d3JicnXj[ZB1d3JiaX6gVFE6KGOnbHzzMEBKSzVyPUG0JI5ONg>? NVLkV3BHOTV5N{G0NVk>
Sf9 cells MonRSpVv[3Srb36gZZN{[Xl? MoTSNlAhdWmwcx?= M37XXmlvcGmkaYTpc44hd2ZiaIXtZY4hTnmwIHX4dJJme3OnZDDpckBU\jliY3XscJMh[W[2ZYKgNlAhdWmwczDifUBGVEmVQTDpckBxemW|ZX7j[UBw\iBzIIXtc4wwVCCDVGCsJGlEPTB;MUWgcm0v NETqU3oyPzNzNUi1Ny=>
human PBMC NF3Lc2VHfW6ldHnvckBie3OjeR?= NE\GVmkzPCCq MWLTeZBxemW|c3nvckBw\iCLTEKgdJJw\HWldHnvckBqdiCqdX3hckBRSk2FIHHmeIVzKDJ2IHjyd{BjgSCHTFnTRUwhUUN3ME2xOkBvVS5? MV6xPFU5PTB2Nh?=
human A549 cells NXPGVZNUS3m2b4TvfIlkyqCjc4PhfS=> NGXkNVM1QCCq NXXYXYRTS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6KCxiSVO1NF0zOCCwTT6= NUDkfHdbOjV6MkW5N|Q>
human CEM cells NHvFfGVEgXSxdH;4bYPDqGG|c3H5 NFjYcVQ4OiCq NWjiW4kyS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hS0WPIHPlcIx{KGGodHXyJFczKGi{czDifUBE[WylZXnuJGFOKGG|c3H5MEBKSzVyPUKzJI5ONg>? NVewSXZoOjJ7MkGwPFE>
human HeLa cells M2X3TGN6fG:2b4jpZ:Kh[XO|YYm= MUS0PEBp NWnsTIwxS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWOYTDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVI2KG6PLh?= MXeyOVgzPTl|NB?=
human PC3 cells MkflR5l1d3SxeHnjxsBie3OjeR?= NGXjU3o1QCCq M4Tpd2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHBEOyClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5JEwhUUN3ME2zNUBvVS5? M3LYeFI2QDJ3OUO0
human SF268 cells MYXDfZRwfG:6aXRCpIF{e2G7 NEXUeJI1QCCq NW\Ee3ZJS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0Z{NkigZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiR1m1NF01PCCwTT6= NWL0SGFDOjF3MUOyPVQ>
human MCF7 cells NXrVWIE{S3m2b4TvfIlkyqCjc4PhfS=> NH3Jdlc1QCCq NYn1fIhOS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVUxKG6PLh?= MlrINlE{QDhzOUG=
HEK293 cells NWPaTFdRS3m2b4TvfIlkyqCjc4PhfS=> NIPzbWo4OiCq NHv4V3dEgXSxdH;4bYNqfHliYXfhbY5{fCCKRVuyPVMh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSnclfsc{Bie3OjeTygTWM2OD13NjDuUU4> M1z2fFI1PzZ|Mk[y
HUE cells NGj6WXdHfW6ldHnvckBie3OjeR?= NH7EblQ6OCCvaX7z NVn2XGlJUW6qaXLpeIlwdiCxZjDWSWdHWjJiaX6gTHVGKGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gWmVITi2rbnT1Z4VlKGG3dH;wbI9{eGixconsZZRqd25idILlZZRm\CCob4KgPVAhdWmwczDi[YZwemViVlXHSkBkcGGubHXu[4Uh[nliRVzJV2EtKEmFNUC9O|Ahdk1w NHzk[|IzODF5MEG2Ny=>
human A431 cells MkPCR5l1d3SxeHnjxsBie3OjeR?= NGq2fYczPCBiaB?= NH3sU|dEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCPDNzIHPlcIx{KGGodHXyJFI1KGi{czD1d4lv\yCDbn7lfIlvKF[nRlnUR{9xem:yaXTpeY0hcW:maXTlJJN1[WmwaX7nJIJ6KE2WVDDhd5NigSxiSVO1NF04OCCwTT6= MnfINlI2PDFyNUG=
human Jurkat cells NVq5R5lsWHKxbHnm[ZJifGmxbjDhd5NigQ>? NY\oe29ISW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBLSUt|IHX4dJJme3OrbnegTWwzNXO2aX31cIF1\WRiaIXtZY4hUnW{a3H0JINmdGy|LDDJR|UxRTdzIH7NMi=> NIXlZZoyQTR{N{KwNy=>
HEK293 cells M1;HPWZ2dmO2aX;uJIF{e2G7 NVH2[WdLUW6qaXLpeIlwdiCxZjDJUE05KHKnbHXhd4Uh[nliSFXLNlk{KGOnbHzzJIV5eHKnc4PpcochWEuFLXLleIEzNCCLQ{WwQVc4KG6PLh?= M1nzeFE2PzdzNEG5
human KE-97 cells M4rCbGN6fG:2b4jpZ:Kh[XO|YYm= Mlz0O|IhcA>? NE\PbodEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBMTS17NzDj[YxteyCjZoTldkA4OiCqcoOgZpkhS2WubGTpeJJmNUeubzDseY1qdmW|Y3XueEBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF|IN88UU4> NUHseWxYOjR|MkiyPFM>
human CHOK1 cells MnT5R5l1d3SxeHnjxsBie3OjeR?= NHvWSYg1QCCq MXrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDDTG9MOSClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG|c3H589yNKEmFNUC9NE4yOyEQvF2u MVuyNVUyOzJ7NB?=
mouse NIH/3T3 cells NVzicnRjS3m2b4TvfIlkyqCjc4PhfS=> Mn76PVYhcA>? NVrpU5dqS3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhVkmKL{PUN{Bk\WyuczDh[pRmeiB7NjDodpMh[nliU2LCJIF{e2G7LDDJR|UxRTBwMjFOwG0v NGHxb2ozPDN4MUWyNS=>
human A2780 cells NVLLU|ZrS3m2b4TvfIlkyqCjc4PhfS=> MkHrPVYhcA>? NF\Te21EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCOjd6MDDj[YxteyCjZoTldkA6PiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwQVAvOiEQvF2u M3XnOFI1OzZzNUKx
human 8505C cells NF31cllEgXSxdH;4bYPDqGG|c3H5 MXi5OkBp NGW1XHdEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckA5PTB3QzDj[YxteyCjZoTldkA6PiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwQVAvOiEQvF2u MX[yOFM3OTV{MR?=
human 518A2 cells NIPUNotEgXSxdH;4bYPDqGG|c3H5 NVXQcoN3QTZiaB?= MXPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjC1NVhCOiClZXzsd{Bi\nSncjC5OkBpenNiYomgV3JDKGG|c3H589yNKEmFNUC9NE4zKM7:TT6= NFz3O|YzPDN4MUWyNS=>
human HuH7 cells NH\JW3hEgXSxdH;4bYPDqGG|c3H5 MX[3NkBp MmTsR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTJVJPyClZXzsd{Bi\nSncjC3NkBpenNiYomgR4VtdFSrdILlMWdtdyCudX3pcoV{[2WwdDDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlI{KM7:TT6= NEO3SmEzPDN{OEK4Ny=>
FL5.12-Akt1 cells NVWxXmJ6WHKxbHnm[ZJifGmxbjDhd5NigQ>? M2\aTGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgSmw2NjF{LVHreFEh[2WubIOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvOjlizszNMi=> MVWxOlQxOzZ{Nh?=
human MiaPaCa-2 cells MkD1VJJwdGmoZYLheIlwdiCjc4PhfS=> MlHNRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPaXHQZWNiNTJiY3XscJMtKEmFNUC9NE4{PyEQvF2u NED1b2wyPjRzM{e4NC=>
human BGC823 cells M{Cxc2N6fG:2b4jpZ:Kh[XO|YYm= M4T5blczKGh? NX\zXpJlS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSkeFOEKzJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1emVvR3zvJIx2dWmwZYPj[Y51KGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwM{ig{txONg>? MUmyOFMzQDJ6Mx?=
human MCF7 cells NELFS4tEgXSxdH;4bYPDqGG|c3H5 NUP0dFg3QTZiaB?= NXe0WYhIS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCjZoTldkA6PiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwQVAvPCEQvF2u NFPaNXczPDN4MUWyNS=>
human A549 cells NYr1fmRNS3m2b4TvfIlkyqCjc4PhfS=> MX65OkBp M1\JOmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[W[2ZYKgPVYhcHK|IHL5JHNTSiCjc4PhfUwhUUN3ME2wMlYh|ryPLh?= NFrHOWYzPDN4MUWyNS=>
HEK293 cells MoLRR5l1d3SxeHnjxsBie3OjeR?= NUXUN5RwS3m2b4TvfIlkcXS7IHHnZYlve3RiSFXLNlk{KGOnbHzzMEBGSzVyPUKg{txONg>? NEf3[3EzPTNzNkOxOy=>
human Raji cells  NWPKd3BJS3m2b4TvfIlkyqCjc4PhfS=> NV\pOG5ZS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWmGsaTDj[YxteyxiRVO1NF0zKM7:TT6= M4\DcFI2OzF4M{G3
human HepG2 cells M2fUVWN6fG:2b4jpZ:Kh[XO|YYm= M2XTO2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmeEd{IHPlcIx{NCCHQ{WwQVIh|ryPLh?= NXTEdY1mOjV|MU[zNVc>
human BJ cells MV3DfZRwfG:6aXRCpIF{e2G7 M{PJUmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGJLKGOnbHzzMEBGSzVyPUKg{txONg>? MoXZNlU{OTZ|MUe=
human U937 cells MYrDfZRwfG:6aXRCpIF{e2G7 M4rh[GN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHU6OzdiY3XscJMtKEmFNUC9NkDPxE1w MVixO|A5QDB4Nx?=

多くの細胞株試験データを見る場合、クリックしてください

体内試験 In the gerbil and rat ischemia models, Staurosporine pretreatment (0.1-10 ng) before ischemia prevents neuronal damage in a dose-dependent manner, suggesting the involvement of PKC in CAl pyramidal cell death after ischemia. [8]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

Enzyme assay and binding assay:

Protein kinase C is assayed in a reaction mixture (0.25 mL) containing 5 μmol of Tris/HCl, pH 7.5, 2.5 μmol of magnesium acetate, 50 μg of histone II S, 20 μg of phosphatidylserine, 0.88 μg of diolein, 125 nmol of CaCl2, 1.25 nmol of [γ-32]ATP (5-10 × 104 cpm/nmol) and 5 μg of partially purified enzyme. The binding of [3H]PDBu to protein kinase C is determined: Reaction mixture (200 μL contained 4 μmo1 of Tris/malate, pH 6.8, 20 μmol of KCl, 30 nmol of CaC12, 20 μg of phosphatidylserine, 5 μg of partially purified protein kinase C, 0.5% (final concentration) of DMSO,10 pmol of [3H]PDBu (l-3 × 104 cpm/pmol) and 10 μL of various amounts of Staurosporine.
細胞試験:

[3]

+ 展開
  • 細胞株: PC12
  • 濃度: Dissolved in DMSO, final concentration 1 μM
  • 反応時間: ~32 hours
  • 実験の流れ:

    Cells are exposed to Staurosporine for ~32 hours. Cells are fixed in 4% paraformaldehyde and stained with the DNA-binding dye Hoechst 33342. Cells are visualized under epifluorescence illumination, and the percentage of apoptotic cells (cells with condensed and fragmented DNA) is determined.


    (参考用のみ)
動物試験:

[8]

+ 展開
  • 動物モデル: Male Mongolian gerbils or male Wistar rats subjected to transient ischemia
  • 製剤: Dissolved in DMSO, and diluted in saline
  • 投薬量: ~10 ng
  • 投与方法: Stereotaxically administered into the bilateral CAl subfield of the hippocampus
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 4 mg/mL (8.57 mM)
Water Insoluble
Ethanol Insoluble

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 466.53
化学式

C28H26N4O3

CAS No. 62996-74-1
保管
別名 CGP 41251

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00301938 Completed Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Acute Promyelocytic Leukemia (M3)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Blastic Phase Chronic Myelogenous Leukemia|Myelodysplastic/Myeloproliferative Neoplasms|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|T-cell Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) December 2005 Phase 1
NCT00098956 Completed Extensive Stage Small Cell Lung Cancer|Recurrent Small Cell Lung Cancer National Cancer Institute (NCI) January 2005 Phase 2
NCT00082017 Completed Lymphoma, Large-Cell, Ki-1|Lymphoma, T-Cell National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 2004 Phase 2
NCT00072267 Completed Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer University Health Network, Toronto|National Cancer Institute (NCI) January 2004 Phase 2
NCT00072189 Terminated Recurrent Melanoma|Stage IV Melanoma National Cancer Institute (NCI) November 2003 Phase 2
NCT00030888 Unknown status Kidney Cancer University of California, San Francisco|National Cancer Institute (NCI) December 2002 Phase 2

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

PKC信号経路図

相関PKC製品

Tags: Staurosporineを買う | Staurosporine ic50 | Staurosporine供給者 | Staurosporineを購入する | Staurosporine費用 | Staurosporine生産者 | オーダーStaurosporine | Staurosporine化学構造 | Staurosporine分子量 | Staurosporine代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID